These findings therefore establish a new and important clinical relevance to the recently described association between TM6SF2 and NAFLD, and suggest that TM6SF2 should be considered alongside PNPLA3 (refs 8, 12) and GCKR9, 29, 30, as one of a handful of genes so far identified that are associated not only with variations in hepatic triglyceride accumulation but also with fibrogenesis7. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.